6th October 2000

Public-Private Consortium to Accelerate Sequencing of Mouse Genome

Results will expedite discovery of human genes

The National Institutes of Health, the Wellcome Trust and three private companies today announced they have formed a consortium to speed up the determination of the DNA sequence of the mouse genome. The Mouse Sequencing Consortium will provide $58 million over the next six months to decipher the mouse genetic code.

Members of the Mouse Sequencing Consortium (MSC) and their contributions to the effort are SmithKline Beecham ($6.5 million), the Merck Genome Research Institute ($6.5 million), Affymetrix, Inc. ($3.5 million), the Wellcome Trust ($7.75 million), and seven of the National Institues ($34 million*), including the National Cancer Institute, the National Human Genome Research Institute, the National Institute on Deafness and Other Communication Disorders, the National Institute of Diabetes and Digestive and Kidney Disease, and the National Institute of Mental Health.

MSC funds will support mouse genome sequencing at three DNA sequencing laboratories: the Whitehead Institute for Biomedical Research in Cambridge, Mass., Washington University School of Medicine in St. Louis, and the Sanger Centre in the U.K.

The MSC is another example of an emerging model for supporting large-scale genomics research in which public and private sector entities join forces to produce publicly available data sets that are crucial for basic biomedical research.

Like the efforts of The SNP Consortium (a group of pharmaceutical and technology companies that together with the Wellcome Trust are constructing a map of genetic variations that occur throughout human DNA) and the Merck-funded effort to generate a database of expressed sequence tags (DNA known to match regions of the genome that code for proteins), the MSC is a public-private partnership to generate data that will be freely available for the unrestricted use of biomedical researchers worldwide. Private sector participation in the MSC has been facilitated by the Foundation for the National Institutes of Health, Inc., a non-profit, charitable organization founded to support the NIH in its mission.

The desire to accelerate mouse genome sequencing builds on the completion in June 2000 of the working draft version of the human DNA sequence. With the working draft of the human genome sequence in hand, scientists in both industry and academia now seek to interpret its meaning. The DNA sequence of the mouse genome will provide an essential tool to identify and study the function of human genes.

Dr Michael Dexter, Director of the Wellcome Trust, said "The Trust sees the mouse sequence as being an essential part of its overall strategy for the translation of sequence information to healthcare benefits. The value of forming the Mouse Sequence Consortium is that by pooling resources this data will be freely available to all much earlier than originally planned. Our membership of this consortium ensures that the UK continues to play a leading role in this important area of scientific research."

Sequencing the mouse genome is now the next major goal of large-scale genomics and the Mouse Sequencing Consortium's effort will expand and accelerate the program to analyze the mouse genome begun by the National Human Genome Research Institute (NHGRI) in September 1999. That program already has generated most of the data for a "fingerprint" map of the mouse genome, including a set of sequences from the ends of cloned genomic DNA fragments, and is doing targeted sequencing of regions of the mouse genome that are of particularly high biological interest. The NHGRI effort also has begun to sequence the mouse genome in its entirety.

Mammals share many basic biological functions such as immune response, regulation of cell division, and development of major organ systems. The gene sequences in mouse and human that encode the proteins to carry out these functions also are shared to a high degree (85% sequence identity). The DNA sequences in the vast regions between genes are much less similar (50% sequence identity or less).

Since only about 5% of the human genome contain genes, sifting through the 3.1 billion DNA letters to find genes is an extremely challenging task. But, by comparing human and mouse genome sequences, the regions of high similarity are readily apparent and immediately identify protein coding regions and regulatory sequences. Thus, the mouse genome sequence will provide a powerful tool to interpret the newly available human genome sequence.

In addition to its use to aid the interpretation of the human genome, the mouse genome sequence also will increase the ability of scientists to use the mouse as a model system to study and understand human disease, and to develop and test new treatments in ways that can not easily be done with humans.

The genome of the mouse is the same size as that of the human, about 3.1 billion base pairs. As recommended by scientists studying the mouse, the genome sequencing effort will use a strain of mouse known as C57BL6/J, commonly called "Black 6." The sequencing strategy that will be used takes advantage of the best features of the map-based shotgun strategy used by the public sequencing consortium to produce the human sequence and the whole genome shotgun strategy used by the private sector effort that also produced a version of the human genome sequence in the past year. The melding of these two strategies promises to produce a high quality genome sequence more quickly than either strategy could alone.

The MSC's program will, by the end of February 2001, bring the overall depth of coverage of the mouse genome to 2.5X to 3X. This is the level of coverage at which shotgun genomic sequence first becomes useful to the typical scientist, with about 93 to 95 percent of the sequence of the mouse genome being available albeit in small, unordered fragments. Subsequently, the mouse genome sequencing effort will generate the complete sequence coverage and assemble the entire sequence into a "finished," highly accurate form.

The data release practices of the MSC will continue the international Human Genome Project's sequencing program's objective of making sequence data available to the research community as soon as possible for free, unfettered use.In fact, the incorporation of the whole genome shotgun sequencing component has led to adoption of a new, even more rapid data release policy whereby the actual raw data (that is, individual DNA sequence traces, about 500 bases long, taken directly from the automated instruments) will be deposited regularly in a newly-established public database operated by the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/) and a sister database operated by the European Bioinformatics Institute (EBI, http://www.ebi.ac.uk/). These individual DNA sequences will be assembled into larger assemblies as soon as sufficient coverage is attained, which will be at about the point where working draft quality coverage of the genome is reached.

* Precise funding levels for the National Institutes of Health are contingent upon final fiscal year 2001 budget appropriations to be passed by the U.S. Congress.


For release: Friday, October 6, 2000 12:01 am Contact for the Consortium
Mary Prescott
001-312-397-6604
mprescott@bsmg.com
(note to reporters/editors:
see last pages for more contacts)

For more information:

Mouse Sequencing Consortium Members Media Contacts
SmithKline Beecham Graeme P. Holland
01279-644269
Graeme_P_Holland@sbphrd.com
Rick Koenig
001-610-270-5546
Rick_M_Koenig@sbphrd.com
Merck Genome Research Institute Kathryn Munoz
001-908-423-6492
kathryn_munoz@merck.com
Affymetrix, Inc. Anne Bowdidge
001-408-731-5925
anne_bowdidge@affymetrix.com
National Cancer Institute NCI Press Office
001-301-496-6641
National Human Genome Research Institute Cathy Yarbrough
001-301-594-0954
cyarbrou@mail.nih.gov
National Institute on Deafness and Other Communication Disorders Marin Allen
001-301-496-7243
marin_allen@nih.gov
National Institute of Diabetes and Digestive and Kidney Diseases Joan Chamberlain
001-301-496-3583
joan_chamberlain@nih.gov
National Institute of Mental Health Marilyn Weeks
001-301-443-4536
mweeks@nih.gov
National Institute of Neurological Disorders and Stroke Margo Warren
001-301-496-5751
mw76v@nih.gov
Wellcome Trust Noorece Ahmed
020-7611-8540
n.ahmed@wellcome.ac.uk
Genome Sequencing Centers Media Contacts
Whitehead Institute for Biomedical Research Seema Kumar
001-617-258-6153
kumar@wi.mit.edu
Washington University School of Medicine Joni Westerhouse
001-314-286-0120
joniw@medicine.wustl.edu
Sanger Centre Don Powell
01223-494956
don@sanger.ac.uk
Foundation for the National Institues of Health, Inc. Constance U. Battle, MD
001-301-402-5311
cubattle@fnih.org
Other Contacts  
  Arthur Holden
001-773-867-2990
aholden@earthlink.net

Contact the Press Office

Don Powell Media and Public Relations Manager
Wellcome Trust Sanger Institute, Hinxton, Cambs, CB10 1SA, UK

Tel +44 (0)1223 496 928
Mobile +44 (0)7753 775 397
Fax +44 (0)1223 494 919
Email press.office@sanger.ac.uk

* quick link - http://q.sanger.ac.uk/yq1bcc1x